Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial † †This article is accompanied by the Editorial. ‡ ‡Declaration of interest. R. M. Grounds has worked in the past as a consultant for Novo Nordisk and has lectured at symposiums organized by Novo Nordisk. Novo Nordisk has given an unrestricted educational grant to St George’s Hospital Special Trustee’s. The trial was funded by Novo Nordisk, UK
| Autor: | Jonathan Ball, J. W. Redman, RM Grounds, G. Maloney, R Raobaikady |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
biology business.industry Vascular disease Placebo-controlled study Blood volume medicine.disease Placebo Intensive care unit Thrombosis law.invention Surgery Anesthesiology and Pain Medicine law Recombinant factor VIIa Anesthesia biology.protein Coagulopathy Medicine business |
| Zdroj: | British Journal of Anaesthesia. 94:586-591 |
| ISSN: | 0007-0912 |
| DOI: | 10.1093/bja/aei102 |
| Popis: | Background Activated recombinant coagulation factor VII (rFVIIa) effectively prevents and controls bleeding in patients with coagulopathy. Data show that rFVIIa may reduce blood loss and eliminate the need for transfusion in patients with normal haemostasis undergoing major surgery. We assessed the efficacy of rFVIIa in patients with normal haemostasis undergoing repair surgery of major traumatic fracture of the pelvis or the pelvis and acetabulum, who were expected to have a large volume of blood loss. Methods We performed a double-blind, randomized, placebo-controlled trial involving 48 patients undergoing major pelvic–acetabular surgery. Patients were randomized to receive an i.v. bolus injection of rFVIIa 90 μg kg−1 or placebo as add-on therapy at the time of the first skin incision. All patients also received intraoperative salvaged red blood cells (RBC). Results There was no significant difference in the total volume of perioperative blood loss, the primary outcome variable, between the rFVIIa and placebo groups. In addition, there were no differences between the two groups in the total volume of blood components, including salvaged RBC transfused, number of patients requiring allogeneic blood components, total volume of fluids infused, total operating time, time taken after entry to the intensive care unit to reach normal body temperature and acid–base status, and time spent in hospital. No adverse events, in particular thromboembolic events, were reported in either group. Conclusions In patients with normal haemostasis undergoing repair surgery of traumatic pelvic–acetabular fracture, the prophylactic use of rFVIIa does not decrease the volume of perioperative blood loss. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|